Nightingale Awarded as One of the Most Innovative Biotech SMEs in Europe
Nightingale Health has been awarded as one of the Most Innovative Biotech SMEs in Europe by EuropaBio (The European Association for Bioindustries). Nightingale’s CEO, Teemu Suna, addressed European biotech leaders and EU policy-makers at an awards ceremony held at the European Parliament on Wednesday.
"It’s an honor to receive recognition from EuropaBio’s jury panel of biotech experts and be invited to speak at the EU parliament. We believe our blood analysis technology has the potential to make a considerable contribution to society through improving early disease detection in healthcare, particularly in primary care. By allowing patients to take an active role in their own health maintenance, we can switch the focus in healthcare from treatment to prevention," says Teemu.
The Most Innovative European Biotech SME Awards is an annual initiative run by EuropaBio, Europe’s largest and most influential biotech industry group. The awards recognize small and medium biotech companies (SMEs) for the societal benefits of their innovations and their contributions to Europe’s economy. EuropaBio is engaged in dialogue with the European Parliament, the European Commission and the Council of Ministers to influence legislation on biotechnology.
At the awards ceremony hosted by Awards Jury Member and MEP Paul Rubig, Nightingale presented its analysis service which provides molecular-level health data from blood biomarker analysis, assisting clinicians in providing more personalized guidance to patients. In the long-term, Nightingale plans to fully integrate its service into healthcare systems and provide tools for patients to follow-up their own health, enabling preventative and personalized healthcare for chronic diseases. Earlier this year, Nightingale was selected as one of the winners of MIT’s (Massachusetts's Institute of Technology) Solve competition, hosted at the United Nations HQ. Nightingale was selected as an official MIT Solver in the Chronic Diseases category.
Teemu Suna, CEO, Founder & Chairman
+358 40 196 1669
About Nightingale Health
Nightingale Health Ltd. is the innovator of an internationally recognized NMR (Nuclear Magnetic Resonance) based biomarker analysis assay for early disease detection. Our aim is to solve the growing burden of cardiovascular disease and diabetes, accounting for healthcare costs of over 1.6 trillion dollars annually. Our pioneering precision medicine services, include: effective chronic disease screening, health diagnostics and improving treatment efficacy. By providing our customers with accurate health data, we plan to help empower patients to follow-up on their own well-being and take proactive steps to stay healthy.
For more information, please visit https://www.nightingalehealth.com